This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk06: Good day, and thank you for standing by, and welcome to Ensign Group Incorporated's second quarter fiscal year 2023 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To remove yourself from the queue, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Chad Keech, Chief Investment Officer. Please go ahead.
spk04: Thank you, Operator, and welcome, everyone. We filed our earnings press release yesterday, and it is available on the investor relations section of our website at EnzymeGroup.net. A replay of this call will also be available on our website until 5 p.m. Pacific on Friday, August 25, 2023. We want to remind any listeners that may be listening to a replay of this call that that all statements made are as of today, July 28, 2023, and these statements have not been nor will be updated subsequent to today's call. Also, any forward-looking statements made today are based on management's current expectations, assumptions, and beliefs about our business and the environment in which we operate. These statements are subject to risks and uncertainties that could cause our actual results to materially differ from those expressed or implied on today's call. Listeners should not place undue reliance on forward-looking statements and are encouraged to review our SEC filings for more complete discussion of factors that could impact our results. Except as required by federal securities laws, Ensign and its affiliates do not undertake to publicly update or revise any forward-looking statements where changes arise as a result of new information, future events, changing circumstances, or for any other reason. In addition, the Ensign Group is a holding company with no direct operating assets, employees, or revenues. Certain of our wholly owned independent subsidiaries, collectively referred to as the service center, provide accounting, payroll, human resources, information technology, legal, risk management, and other services to the other operating subsidiaries through contractual relationships with such subsidiaries. In addition, our wholly owned captive insurance subsidiary, which we refer to as the insurance captive, provides certain claims made coverage to our operating companies for general and professional liability as well as for workers' compensation insurance liabilities. Enzyme also owns Standard Bear Healthcare REIT, Inc., which is a captive real estate investment trust that invests in healthcare properties and enters into lease agreements with certain independent subsidiaries of Enzyme, as well as third-party tenants that are unaffiliated with the Enzyme Group. The words Enzyme, Company, We, Our, and Us refer to the Enzyme Group, Inc., and its consolidated subsidiaries. All of our operating subsidiaries, the Service Center, Standard Bear Healthcare REIT, and the insurance captive are operated by separate, wholly owned, independent companies that have their own management, employees, and assets. References herein to the consolidated company and its assets and activities, as well as use of the words we, us, our, and similar terms we may use today, are not meant to imply, nor should it be construed as meaning that the Enzyme Group has direct operating assets, employees, or revenue, or that any of the subsidiaries are operated by the Enzyme Group. Also, we supplement our GAAP reporting with non-GAAP metrics. When viewed together with our GAAP results, we believe that these measures can provide a more complete understanding of our business, but they should not be relied upon to the exclusion of GAAP reports. A GAAP to non-GAAP reconciliation is available in yesterday's press release and is available in our form 10-Q. And with that, I'll turn the call over to Barry Port, our CEO. Barry?
spk03: Thanks, Chad, and thank you everyone for joining us today. We're very happy with the record results we reported this quarter as our local leaders and their teams achieved excellent clinical and financial results, even when the operating environment continues to present challenges. During the quarter, we saw continued improvement in occupancy, skilled revenue, skilled days, and managed care revenues, which is particularly impressive given persistent labor market pressures and the return of more typical seasonality. As we anticipated in our last report, we saw fewer admissions in the second quarter, which is typical in the summer months as seasonal factors impact patient flow. However, our occupancy performance remained strong with same-store occupancy of 78.5% as of the end of the quarter, which was an increase of 3.97% over the prior year quarter. We are confident that we're on a path to reach and eventually exceed our pre-COVID same store occupancy of 80.1% as we move into the hired mission months of fall and winter. In addition, we may never have seen as much potential to drive organic growth across our portfolio than we do right now. There are so many opportunities in front of us to improve labor and drive occupancy and skilled mix as we continue to successfully transition 45 recently acquired operations. We are very excited to see our local field and service center partners share and apply best practices as they respond to the significant labor market challenges. As they instill our customer second culture into each operation, we have seen and will continue to see lower turnover and less usage of third-party nursing agencies, which again improved for the sixth month in a row as of June 30th. We also see the enormous growth opportunities in SAMHSA occupancy and enhancing our ability to care for skilled patients in a way that best serves each unique healthcare market. During the quarter, our SAMHSA operations grew skilled next revenue and skilled next days by 8.8% and 5.6% respectively over the prior year quarter. We also continue to build stronger relationships with our managed care partners due to the better coordination of care increased capabilities, and strong clinical outcomes. As a result, we saw increased volume in our same store and transitioning combined managed care census and managed care revenue, which increased during the quarter by 8.2% and 12.2%, respectively, over the prior year. As we indicated last quarter, we continue to see that our skilled mix for both revenue and census remains elevated when compared to pre-COVID levels. showing just how important high-quality post-acute services are within the continuum of care. We continue to demonstrate our ability to find, transition, and improve our recently acquired operations. We are encouraged to see our ability to transition new operations continue to improve with each and every acquisition, both in larger and smaller deals. Because we've demonstrated a track record for successfully transitioning operations throughout our history, We sometimes worry that we under-emphasize how truly remarkable these transformations are. The process each operation goes through to achieve the clinical and financial results we expect is so complex and varies so much building by building, it's difficult to describe unless you've seen it close up. But this is where our local approach really shines. With the support of local cluster and service center experts, each leadership team is empowered to implement the changes their operation demands down to every aspect of clinical offerings and expense management. So when we see these results in many of these operations across diverse set of locations, all in a relatively short period of time, it shows that we are learning and improving each time we grow. We expect some of these operations to face some transitional growth pains during the year, including some pressures on occupancy that are typical during the summer months, but we can't wait to see how these operations continue to contribute to our results as they mature, and we look forward to many, many more like them in the near and long-term future. Due to our solid skilled mix and occupancy growth, as well as continued strength from our recent acquisitions, we are increasing and narrowing our annual 2023 earnings guidance to between $4.70 and $4.78 per diluted share, up from $4.64 to $4.77 per diluted share. This new midpoint of our 2023 earnings guidance represents an increase of 14.5% over our 2022 results and is 30.2% higher than our 2021 results. We're also raising our annual revenue guidance to between $3.69 billion and $3.73 billion, up from our previous guidance of $3.68 billion to $3.73 billion. This increased guidance comes on top of the enormous growth we experienced in the last few years. To put this performance in perspective, since we spun out the pennant group in 2019, we have seen adjusted EPS grow by 166%, with a compound annual growth rate of 27.7%. This performance is not due to some large event or a single transformative transaction, but instead is the result of consistent growth and performance quarter after quarter that comes from following proven InSign principles. We are excited about the upcoming year and confident that our partners will continue to manage and innovate through all the lingering challenges on the labor front. All of these results we have talked about today are only made possible by the relentless efforts of our leaders, caregivers, and their continued endurance and strength, all while many of them were helping transition 45 recently acquired operations. We look forward to even more clinical and financial success during the remainder of the year as our focus is following and protecting the operational principles that got us here. Now, I'll ask Chad to provide some additional insights regarding our recent growth. Chad?
spk04: Thank you, Barry. After adding 19 operations last quarter, we took some much needed time to continue to work together with our new teams and all 45 of our newly acquired operations as they continue to adopt Ensign's cultural principles. We couldn't be more excited about the organic growth potential within our existing portfolio as our new acquisitions are already contributing to our results in many cases ahead of schedule. As a result of skilled services expansions in the first half of 2023, occupancy and skilled mixed days for the skilled nursing operations in the recently acquired bucket was 77.2% and 28% respectively for the quarter. For those that have been following us for years will note, this is a very impressive starting point from which to build. However, when compared to our same store occupancy and skilled mixed days, of 78.5% and 32.3% respectively, there is enormous upside in each of these operations as they continue to transform into same store caliber operations. As we evaluate the horizon for new deals, we are well down the road on several opportunities and, assuming everything goes as planned, we expect to announce a handful of new acquisitions in the very near future. The pipeline has been steady over the summer and we expect more opportunities to arise in the fall as we approach the end of the year. The past few years have been very difficult for skilled nursing operators and we see evidence of that in the low occupancy and high utilization of third-party nursing agencies and the poor clinical and financial health of the facilities we have recently acquired. As a result, we still expect that there will be lots of opportunities that will arise. However, as we always remind you, We do not set arbitrary growth goals and remain true to our discipline acquisition strategy, only growing when we have the right leaders in place and the pricing is right. We continue to look at opportunities in new states, but as we've said before, entering new states is challenging and can often take time to gain the trust of the local healthcare community. With the success we continue to enjoy in South Carolina, we hope that we will be able to continue to build Enzyme's footprint in nearby southern states. That said, we will always place the highest priority on growth opportunities within our existing footprint. As we carefully select our acquisition targets, we prioritize those that give us exposure to new markets and states we already operate in, or that enhance our service offerings and markets we've been in for years. Our real estate investment trust, Standard Bearer, continues to evaluate a steady flow of deal opportunities that would potentially include leases with several unaffiliated tenants. in addition to providing opportunities for Ensign affiliated operations. In fact, we expect to announce just such a transaction in the coming weeks. However, we also want to remind you that we are being very careful not to dilute the health of our current portfolio in the name of diversification. As potential transactions cross our desks, we are first focused on the fundamental principles that have led to Ensign's success, including ensuring that the operator has a fantastic leadership team and that the purchase price will result in a rent payment that will ensure a healthy operation over both the near and long term. We are committed to those principles and are in no hurry to de-worsify our billion-dollar portfolio that we have spent years building just for the sake of growth. As of the end of the quarter, Standard Bearer, which is comprised of 103 owned assets, generated rental revenue of $19.9 million for the quarter. of which $16.1 million was derived from enzyme-affiliated operations. Also for the quarter, Standard Bearer produced $13.3 million in FFO and had an EBITDA to rent coverage ratio of 2.4 times. And with that, I will turn the call to Spencer, our COO, to add more color around our operations. Spencer?
spk00: Thank you, Chad, and hello, everyone. As Barry and Chad just noted, acquisitions represent an extremely important part of our operational strategy. This is particularly true right now as we are absorbing 45 facilities that were acquired over the last 12 months. While many of these new facilities are following the typical multi-year turnaround process to reach their potential, we've been pleased to see the quicker than average contributions that some of our recent acquisitions are making, clinically and financially. One great example of this is Fairmont Rehab Hospital, located in Lodi, California. This 59-bed skilled nursing and rehab center had a good reputation in the community prior to transition, thanks in part to the leadership of longtime executive director Randy Tu and director of nursing, Genebeth Devera. Despite their prior history of success, Randy and Genebeth truly embraced the cluster model. as well as the sophisticated tools and data that our organization provides to help affiliated operations succeed at the day-to-day fundamentals. As a result, over the past five months, the Fairmont team has already made a meaningful EBIT contribution. In addition, they've successfully eliminated third-party nursing agencies and reduced overall nursing labor expenses, while simultaneously growing revenues, occupancy, and skilled mix, All this while maintaining a CMS five-star overall rating, as well as a five-star rating for health inspections and quality measures. However, with the focus and excitement that surrounds new transitions, it's important that we don't overlook the greatest contributor to our ongoing success, consistent year-over-year improvement in our same store operations. One exceptional example of this is Beacon Hill Rehabilitation, located in Longview, Washington. This CMS five-star rated, 67-bed skilled operation is led by CEO Steve Ross and COO Amanda Ogden. It was acquired in 2014 and after transitioning has been able to achieve five straight years of financial improvement while serving as Longview's facility of choice. Despite years of high performance, Beacon Hill grew revenues by 13% in the second quarter compared to the prior year quarter. Even more impressive, year-to-date EBIT is trending 47% ahead of last year through the first half of the year. More than just focusing on their own success, though, the leadership team at Beacon Hill has led through the cluster model and found ways to improve the results of the other 12 facilities in the Washington market. One particularly impressive example of this is how Beacon eliminated their own reliance on third-party nursing agencies late in 2022. and then reached out to share ideas and push the other facilities in their market to do the same. The result is that since April 1st of this year, none of the 13 affiliated facilities in the state of Washington has used even a single shift of agency nursing labor. While there are more incredible success stories than can possibly be shared, we hope that these two examples demonstrate the synergistic mix of newly acquired and same-store contributions that have allowed us to continue to achieve record results, even in today's challenging environment. With that, I'll turn the time over to Suzanne to provide more detail on the company's financial performance and our guidance, and then we'll open up for some questions. Suzanne?
spk05: Thank you, Spencer, and good morning, everyone. Detailed financials for the quarter are contained in our 10Q and press release filed yesterday. Some additional highlights for the quarter include the following. GAAP diluted earnings per share with $1.12, an increase of 10.9%. Adjusted diluted earnings per share was $1.16, an increase of 14.9%. Consolidated GAAP revenues and adjusted revenues were both 921.3 million, an increase of 25.8%. GAAP net income was 64 million, an increase of 10.9%. And adjusted net income was 66.3 million, an increase of 15.4%. Other key metrics as of June 30, 2023 include cash and cash equivalents of $420 million, cash flow from operations of $168.1 million, and $593 million of availability on our revolving line of credit. During the quarter, we paid a quarterly cash dividend of $0.0575 per share. We also delevered our portfolio achieving least adjusted net debt to EBITDA ratio of two times, which is a decrease from last year of 2.03 times, and is particularly impressive given the amount of growth we have taken on over the last year. As of today, we have no updates from the federal government on the anticipated federal minimum staffing rule. However, since our last quarter, we have continued to receive good news on reimbursement that has provided some excellent extra clarity about the remainder of the year. Starting in October of this year, we expect the federal net Medicare rate to increase by a healthy 3.5%. At the state level, most of the states we operate in have already adjusted their reimbursement to offset some of the reimbursement linked to the public health emergency that ended in May. For example, key states like Texas announced some encouraging changes to their rates. the combination of a positive rate environment and the slowing of inflation and some of our biggest costs, including labor, will add to the operational momentum we continue to generate as we focus relentlessly on fundamentals. As Barry mentioned, we are increasing and narrowing our annual 2023 earnings guidance to between $4.70 to $4.78 per diluted share, up from $4.64 to $4.77 per diluted share. We are also rising our annual revenue guidance to between 3.69 billion and 3.73 billion. We have evaluated multiple scenarios and based on the strength in our performance and the positive momentum we've seen in operations and strong skilled mix, as well as some additional strength in Medicaid and managed care programs, we are confident that we can meet this guidance. Our 2023 guidance is based on diluted weighted average common shares outstanding of approximately 57.7 million, a tax rate of 25%, the inclusion of acquisitions closed in 2023, the inclusion of management's expectations for Medicare and Medicaid reimbursement rate, net of provider tax, and with a primary exclusion coming from stock-based compensation. Additionally, other factors that could impact quarterly performance included variation in reimbursement systems, delays and changes in state budgets, the return of seasonality on occupancy and skilled mix, the influence of general economy, census and staffing, the short-term impact of acquisition activities, variations in reinsurance accruals, and other factors. And with that, I'll turn it back over to Barry. Barry?
spk03: Thanks, Suzanne. As we wrap up, it's always important for us to acknowledge our incredible team members, facility leaders, field resources, clinical partners, and Service Center team that are behind these record-setting results. As we reflect on the challenges our partners continue to face from almost every direction, we never cease to be amazed by their impressive resiliency as they focus on supporting one another in new and innovative ways. We can't emphasize enough how incredibly honored and grateful we are to work alongside each of them. Their commitment has really blessed the lives of so many, including our own. We're excited about our future because of these amazing partners. We have complete faith in them and the culture they have collectively built. We'll now turn over to the Q&A portion of our call. Operator, can you please instruct the audience on the Q&A procedure?
spk06: Thank you. As a reminder, to ask a question, you'll need to press star 1-1 on your telephone. To withdraw your question, please press star 1-1 again. Please wait for your name to be announced. Please stand by while we compile the Q&A roster. One moment for our first question, please. Our first question comes from the line of Scott Fidel with Stevens. Your line is now open.
spk01: Great. Hi. Thanks, everyone. Good afternoon. First question, just given, you know, the unusual size of the acquisition with the North American portfolio, I thought it would be helpful if you maybe can walk us through, you know, how the integration has been proceeding on that portfolio and how the margins in particular have been trending there relative to your expectation in the second half and then how you see that setting up as well for continued performance in the back half of the year.
spk03: Yeah, no, I appreciate the question. It's obviously been an important focus of ours to make sure that we, number one, get this culturally right. Anytime we take a larger portfolio of facilities, we certainly worry first and foremost about the cultural integration and making sure that not only do these new partners feel like they're an important part of our organization, but that they learn and understand our operational principles and core values and that they see and feel the vision of what we hope to become together. And we've done some unique things with this transition that have been, I think, really helpful to that end. our leaders were able to have early access to the North American partners and really get them in early and spend time, again, ahead of the transition to help them learn these things and to kind of appreciate the nuances and changes that they were needing to expect. That, combined with some kind of new tools and operational kind of transitional things that we put in place all proved to be really helpful in helping this transition go much, much better and go a lot more efficiently than I think any of us really expected. So while there were some you know, some bigger obstacles up front with some high nursing agency and some other operational adjustments that needed to happen and lower occupancy, especially when compared to our other California operations that certainly had an impact on their existing margins and how they were doing operationally. A lot of those hurdles were overcome really quickly. Now, we're not anywhere where we need to be yet with these operations, but But the transition has been really effective. We've seen a path towards viability and profitability that's been much quicker at each operation than we expected to the point where they're all contributing now. But the good news is they all have a tremendous amount of upside still. And there's a lot more to be done to continue to improve with the vast majority of the leaders that were already in those buildings in the first place, including a really great cohort of amazing clinical leaders in each one of these buildings that have many, many years of experience. And so when you have great operational leaders and great clinical leaders combined with great clusters and ensign partners around them, It's a good formula for success. California is one of our stronger states, and that experience of leadership around these North American buildings has proved to be really effective in helping these leaders come along and feel like they're an important part of our organization.
spk01: Okay, great. Appreciate that. My second question just wanted to just drill into the EBITDA margins a bit. And so if we look at the first half of the year, you came in at 11.3% in the first quarter and 11.2% in the second quarter on an adjusted basis. Clearly a lot of different moving pieces within that in terms of the FMAP starting to wind down a bit, integrating the North American property. You know, as we look out to the back half of the year, obviously we're still waiting on the minimum staffing rule, although that wouldn't be, you know, in effect until later on. And you've highlighted some of these rate increases you're getting. You know, how would you sort of, I guess, sort of without, I know you don't provide quarterly guidance, but think about the slope on margins from here, you know, when we think about the third quarter and the fourth quarter, and then also how you've talked about some of the normal seasonality seeming to have returned, you know, to the business as well.
spk05: Yeah, maybe I'll start and then Barry can fill in the gaps there. And so I think just looking at our history and looking at where seasonality is, historically, right, Q4 is our strongest quarter. Q2 and Q3 tend to be a weaker. You know, I think during COVID we didn't experience that seasonality as the same effect. We do see some seasonality coming in towards the end of – and we saw it coming in towards the end of June – But, you know, and expect that to have a little bit of seasonality this year as we're ramping back into kind of post-COVID times. And so always, we've always had better margins in the fourth quarter relative to Q3. With regards to a couple of other things that are happening in the dynamics of the numbers, We did have a North American acquisition that Barry just got done talking about. And so I think we're looking at an EBITDA number versus an EBITDA number. I think just making sure that we're taking in that full rent calculation associated with some of those newer acquisitions. A lot of the newer acquisitions have been leases. And so I think looking at the EBITDA, you can kind of see that we're pretty consistent quarter over quarter and going from there.
spk03: So I think that that's... Yeah, I think some things that probably support our optimism for maybe some margin expansion towards the end of the year is we continue to make great progress on the agency front. We've seen, as we said in our stated remarks, we've seen those numbers continue to go down for about six months in a row, two full quarters in a row. And then, you know, obviously... Our skilled mix is much stronger than it was pre-COVID, and we see that as a continued opportunity. We have really great relationships with our managed care partners. Our field leaders have become more and more adept at ensuring that they have high-quality and high-acuity service offerings to be able to attract those kinds of patients, and continue to kind of rise up the acuity scale. And so, you know, obviously towards the end of the year is when we see growth, more growth in skilled mix and sicker patients. And so I think those two factors combined will kind of prove to, you know, lead towards a little bit higher margins towards the end of the year.
spk01: Okay, understood. And if I could just ask one more question. Just on the minimum staffing rule, which obviously everyone has sort of been waiting on for quite a period of time here to finally see the content of that. I have two sort of things I was just wondering about with that. I guess the first is, is there anything proactively that that you're looking to do from the operations perspective ahead of this? Or is it really something where you just want to see what the final proposal is and then adjust as necessary? And then from the M&A backdrop and the discussions there, how much, I guess, of the gaining factor has that been either for you guys or for potential sellers in terms of wanting to have visibility into that rule or is that not that significant as you look at M&A discussions? And then that's it for me. Thanks a lot.
spk03: Addressing the last part of that question first, it's interesting how sellers tend to ignore any potentiality of any factor that has, you know, some kind of a headwind effect. So that's always funny to us that, are you seeing something we're not seeing? So, but that said, yes, there's a lot we're doing. I would say on the government relations front, we're very active with our association. We've spent time visiting, you know, D.C. at their request and with folks they want us to meet with and and also providing comments and feedback. And we will engage with our association on a pretty aggressive letter-writing campaign, too, both ahead of and behind any release of the proposed rule around federal staffing. We know that the proposed staffing rule will be coming. You know, there's... We don't think it'll probably be out for another month or so, but what I can tell you that we're doing organizationally is really not reacting much to what we don't know. What we have been focused on is making sure that we continue to be the best employer we can be. We have had an intense focus for the last year and a half on being the employer of choice, to make sure our retention efforts are exceptional, that we're sharing best practices around how to improve on our culture and our principles that we believe deeply in, that we hope make us the place where healthcare workers want to be. And so, you know, a lot of discussion around turnover and best practices around orientation and attracting talent and developing, you know, new employees by having schools and other programs to attract talent. Those have been in place absent a federal staffing minimum rule and will continue to be in place post just in line with what our cultural principles lead us to And the labor challenges really have put all these things in a bigger spotlight for us and really have been a help for us to want to continue on this path of just being better. Whatever the federal staffing minimum rule is, we will address it and we will deal with it as we have with any other headwind or challenge that has been put in our way before. We're not necessarily looking forward to it, but that's the nature of our industry and we're, I think, You know, Ensign was built for times like that, and I think if there is an organization that can and will adapt, we'll be able to do it. So the other last comment I'll make about that, Scott, is that, you know, even when the rule comes out, there's going to be a pretty long comment period around, you know, what that rule looks like before it becomes final. That'll take many, many months. So it'll certainly lead us into the next year, and I think the one thing that we've been given a little bit of clarity, now it could change, is that there's probably going to be a longer lead time as far as the implementation of a federal staffing rule, as you can imagine. So again, this is all conjecture. We try not to spend too much time on it, but that's what we know. I'll just add to the second part of your question there, Scott.
spk04: Certainly As Barry was saying, the deals that we're seeing now, sellers and brokers aren't saying, hey, let's build in some minimum staffing into our pro formas for sure. But all that said, I certainly think that will create some disruption in the market that will generate an enormous amount of opportunity for us. Our strategy will remain the same, however, which is to pay prices that are reflective of reality. And as we do that, I'm confident that, you know, the growth engine that we have will continue to run and we'll have lots of opportunity to do that.
spk01: Okay, great. I appreciate all the color. Thanks.
spk06: Thank you. One moment for our next question, please. And our next question comes from the line of Ben Hendricks. with RBC Capital Markets. Your line is now open.
spk02: Hey, thanks, guys. A quick question on the guidance. I appreciate the commentary about watching EBITDA. I was wondering if you could give us a little idea on the ramp and lease expense you expect to the back half of the year and then where you would expect lease expense to end the year on a run rate basis. Thanks.
spk05: Yeah, so for the most part, right, for acquisitions to date, we didn't have any additional acquisitions in Q3 or Q2, and so that lease amount has kind of that base in it. Most of our leases have caps about higher than 3%, and so kind of having about half of it come in already with some to still come in in the second half is probably a good way to look at that lease expense number.
spk02: Okay, thank you. If I may, one, we're seeing more headlines from health systems about adoption of skilled care in the home. And I'm just wondering to see kind of how you're seeing that trend across your markets. And if you, I think you were in discussions with one health care or health system in particular about a potential home strategy, in-home strategy. I was wanting to get an idea of how that's trending and where that is.
spk03: Yeah, I mean, I think You know, one major comment or kind of one principal comment I would make about that is that I think any shift of patients that we might have from kind of their current setting to a home setting is a really, really tiny percentage. Our focus is on getting our patients out of our setting and into the home setting to the or capable of it as quickly as possible. So that said, there are some things that I think we're looking at that can be done to make that transition better and even look at different strategies and partnerships with physician groups and have a strategy around that successful transition. recently partnered with and invested in a group that is focused on this for kind of a high-risk, high-need population in the San Diego market. And we're exploring that partnership and the synergies we can have with that group and seeing how we can expand it. But again, we're still talking about a really, really tiny part of our current and future business. While there's a lot of discussion around this, I think any major shifts that have taken place have already happened. Remember, we started a home health and hospice company and spun it out eventually. We know that business really well. We know the home setting well. But I don't think we see any massive dynamics that would drastically change our business model in the future, more just kind of nuanced market-by-market strategies for maybe high-risk patient populations.
spk02: Thank you.
spk06: Thank you. I'm currently showing no further questions at this time. I'd like to turn the call back over to Mr. Berryport for closing remarks.
spk03: Thank you, and we look forward to a great year and appreciate everyone's support and for being on the call today.
spk06: That concludes today's conference call. Thank you for your participation. You may now disconnect. Everyone have a wonderful day.
Disclaimer